News coverage about Natera (NASDAQ:NTRA) has trended somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Natera earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave headlines about the medical research company an impact score of 45.1407644179848 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
A number of brokerages recently commented on NTRA. Cowen reiterated a “buy” rating and issued a $12.00 target price on shares of Natera in a research report on Thursday, December 21st. Zacks Investment Research upgraded Natera from a “sell” rating to a “hold” rating in a research report on Wednesday. Robert W. Baird reiterated a “buy” rating on shares of Natera in a research report on Tuesday, October 24th. Canaccord Genuity reiterated a “buy” rating and issued a $15.00 target price on shares of Natera in a research report on Tuesday, November 14th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $16.00 target price (up previously from $13.00) on shares of Natera in a research report on Friday, October 6th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $14.50.
Shares of Natera (NTRA) traded up $0.39 during midday trading on Friday, reaching $10.10. The company had a trading volume of 110,500 shares, compared to its average volume of 101,800. The stock has a market capitalization of $544.68 and a price-to-earnings ratio of -4.16. Natera has a 52-week low of $7.35 and a 52-week high of $14.76. The company has a current ratio of 1.85, a quick ratio of 1.75 and a debt-to-equity ratio of 2.43.
Natera (NASDAQ:NTRA) last issued its earnings results on Wednesday, November 8th. The medical research company reported ($0.51) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.47) by ($0.04). The firm had revenue of $56.66 million during the quarter, compared to analysts’ expectations of $55.31 million. Natera had a negative net margin of 62.34% and a negative return on equity of 197.09%. Natera’s quarterly revenue was up 5.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.50) EPS. sell-side analysts anticipate that Natera will post -2.15 earnings per share for the current year.
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.